Skip Navigation LinksHome > November 2012 - Volume 18 - Issue 11 > Fecal calprotectin concentration predicts outcome in inflamm...
Inflammatory Bowel Diseases:
doi: 10.1002/ibd.22863
Original Article: Original Clinical Articles

Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNFα blocking agents

Molander, Pauliina MD1,2*; af Björkesten, Clas‐Göran MD3; Mustonen, Harri DSc4; Haapamäki, Johanna MD, PhD3; Vauhkonen, Matti MD, PhD6; Kolho, Kaija‐Leena MD, PhD5; Färkkilä, Martti MD, PhD2,3; Sipponen, Taina MD, PhD3

Collapse Box

Abstract

Background:: Fecal calprotectin (FC) concentration is a useful surrogate marker for mucosal healing (MH) during tumor necrosis factor alpha (TNFα)‐blocking therapy for inflammatory bowel disease (IBD). Our aim was to evaluate whether a normal FC after induction therapy with TNFα antagonist predicts the outcome of IBD patients during maintenance therapy.

Methods:: Sixty IBD patients (34 Crohn's disease [CD], 26 ulcerative colitis [UC]), treated with TNFα antagonists, either infliximab (n = 42) or adalimumab (n = 18), and having a documented FC level at baseline and after induction therapy were included. Disease activity was evaluated by partial Mayo score without endoscopy or Harvey–Bradshaw index at baseline, after induction, and at 12 months during maintenance therapy.

Results:: After induction, FC was normalized (≤100 μg/g) in 31 patients (52%, median 42 μg/g, range 0–97), whereas the level remained elevated in 29 patients (48%, median 424 μg/g, range 116–5859). At ≈12 months, 26/31 (84%, 18 CD, 8 UC) of the patients with normal FC after induction were in clinical remission, whereas only 11/29 (38%, 9 CD, 2 UC) of those with an elevated (≥100 μg/g) postinduction FC were in clinical remission, P < 0.0001. After induction therapy with TNFα antagonists, a cutoff concentration of 139 μg/g for FC had a sensitivity of 72% and a specificity of 80% to predict a risk of clinically active disease after 1 year.

Conclusions:: A normal FC after induction therapy with TNFα antagonists predicts sustained clinical remission in the majority of patients on scheduled therapy with active luminal disease. (Inflamm Bowel Dis 2012;)

© Crohn's & Colitis Foundation of America, Inc.

You currently do not have access to this article.

You may need to:

Note: If your society membership provides for full-access to this article, you may need to login on your society’s web site first.

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.